Merck & Co. Inc. (MRK) reports disappointing quarter results with coronavirus pandemic impacting $400 million on fourth-quarter sales. Sales increased 5% to $12.51 billion but missed analyst forecasts for $12.67 billion. Adjusted earnings came in at $1.32 per share missing estimates of $1.38 per share. Sales of Merck’s Keytruda, blockbuster cancer drug increased 28% to $3.99 billion. Sales of Gardasil soared 44% to $998 million, but sales of diabetes drug Januvia dropped 6% to $1.33 billion.
For 2021, Merck expects to earn $6.48-$6.68 per share on $51.8 billion to $53.8 billion in sales ahead of market estimates for earnings of $6.30 per share and $51.7 billion in sales.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.